An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in which Abiraterone Demonstrated Long-term Efficacy.
An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in which Abiraterone Demonstrated Long-term Efficacy.
Intern Med. 2019 Oct 17;:
Authors: Yoshizawa T, Yamaguchi K, Kawata N, Ryuzaki H, Ogawa M, Obinata D, Mochida J, Takahashi S
Abstract
We analyzed the ERG gene status using fluorescence in situ hybridization (FISH) in two chemotherapy-naïve cases with metastatic castration-resistant prostate cancer (mCRPC) in which abiraterone demonstrated a long-term durable complete response. FISH identified Class 1 Edel and Class 2+ Edel in case 1, and Class 1 Edel in case 2. Our experience suggests that abiraterone may be effective in cases with mCRPC and ERG gene abnormalities, particularly Class 2+ Edel or Class 1 Edel. This is the first report of two cases with mCRPC that simultaneously investigated the ERG gene status and clinical aspects, including image evaluations and pathology.
PMID: 31619598 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Fish | Genetics | Internal Medicine | Pathology | Prostate Cancer